Consulta: subjectFacets:"Antiviral therapy"
Registros recuperados: 4
Data/hora: 09/06/2024 04:39:21

Inhibition of equine arteritis virus by an antimicrobial peptide produced by Bacillus sp. P34
Provedor de dados: 45
Autores: Silva,D. Scopel e; Castro,C.C.; Silva e Silva,F.; Costa,G.A.; Soares,M.P.; Vargas,G.D.; Fischer,G.; Lima,M.; Brandelli,A.; Motta,A.S.; Hübner,S.O.
ABSTRACT P34 is an antimicrobial peptide produced by Bacillus sp. P34, isolated from the intestinal contents of a fish from the Amazon basin. This peptide showed antibacterial properties against Gram-positive and Gram-negative bacteria and was characterized as a bacteriocin like substance. It was demonstrated that the peptide P34 exhibited antiviral activity against feline herpesvirus type 1 in vitro. The aim of this work was to evaluate P34 for its antiviral properties in vitro, using RK 13 cells, against the equine arteritis virus, since it has no specific treatment and a variable proportion of stallions may become persistently infected. The results obtained show that P34 exerts antiviral and virucidal activities against equine arteritis virus, probably...
Tipo: Info:eu-repo/semantics/article
Palavras-chave: Equine arteritis virus; Antiviral therapy; Antimicrobial peptide; Virucidal activity.
Ano: 2017
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-09352017000300535

Splenectomy prior to antiviral therapy in patients with hepatitis C virus related decompensated cirrhosis
Provedor de dados: 55
Autores: Fanpu,Ji; Zhang,Shu; Huang,Na; Deng,Hong; Li,Zongfang.
Patients with hepatitis C virus-related decompensated cirrhosis can benefit frominterferonbased antiviral therapy, but the common complication of cytopenia is a contraindication for this treatment. Splenectomy prior to interferon therapy may alleviate this problem. To investigate whether splenectomy improves the efficacy of antiviral therapy, 13 interferonnaïve hepatitis C virus decompensated cirrhotic patients underwent splenectomy between January 2008 and January 2011, followed 1-3 months later by an interferon-based therapeutic regimen (pegylated/standard interferon-α combined with ribavirin for 48 weeks). Ten (76.9%) of the patients developed postoperative complications, which included minor portal vein thrombosis (2/13, 15.4%) and transient ascites...
Tipo: Info:eu-repo/semantics/other
Palavras-chave: Hepatitis C virus; Thrombocytopenia; Splenectomy; Antiviral therapy.
Ano: 2013
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702013000500014

Effect of iron overload on the severity of liver histologic alterations and on the response to interferon and ribavirin therapy of patients with hepatitis C infection
Provedor de dados: 56
Autores: Souza,R.M.; Freitas,L.A.R.; Lyra,A.C.; Moraes,C.F.; Braga,E.L.; Lyra,L.G.C.
The objective of the present study was to determine the presence of hepatic iron overload in patients with chronic HCV infection and to correlate it with histologic alterations, HCV genotype and response to therapy. Liver tissue samples from 95 patients with chronic hepatitis C were divided into two groups: group I, presence of iron overload in hepatic tissue (Perls' staining) and group II, no iron overload. Hepatic iron overload was detected in 30 (31.6%) of 95 patients. Of the 69 patients tested by genotyping, 49 (71.01%) were genotype 1 and 20 (28.99%) genotype non-1. Iron overload was detected in 14 (28.6%) patients with genotype 1 and in 6 (30%) with genotype non-1 (P = 0.906). There was a significant difference in fibrosis stage between groups (P =...
Tipo: Info:eu-repo/semantics/other
Palavras-chave: Hepatitis C infection; Iron overload; Genotype; Inflammatory activity; Fibrosis; Antiviral therapy.
Ano: 2006
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2006000100009

The emergence of YMDD mutants precedes biochemical flare by 19 weeks in lamivudine-treated chronic hepatitis B patients: an opportunity for therapy reevaluation
Provedor de dados: 56
Autores: França,P.H.C.; Coelho,H.S.M.; Brandão,C.E.; Segadas,J.A.; Quintaes,R.F.; Carrilho,F.J.; Ono-Nita,S.; Mattos,A.A.; Tovo,C.; Gouvea,V.S.; Sablon,E.; Vanderborght,B.O.M.
Given the loss of therapeutic efficacy associated with the development of resistance to lamivudine (LMV) and the availability of new alternative treatments for chronic hepatitis B patients, early detection of viral genotypic resistance could allow the clinician to consider therapy modification before viral breakthrough and biochemical relapse occur. To this end, 28 LMV-treated patients (44 ± 12 years; 24 men), on their first therapy schedule, were monitored monthly at four Brazilian centers for the emergence of drug resistance using the reverse hybridization-based INNO-LiPA HBV DR assay and occasionally sequencing (two cases). Positive viral responses (HBV DNA clearance) after 6, 12, and 18 months of therapy were achieved by 57, 68, and 53% of patients,...
Tipo: Info:eu-repo/semantics/article
Palavras-chave: Hepatitis B; Antiviral therapy; Lamivudine; Drug resistance; YMDD variants; Hepatitis B virus.
Ano: 2007
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2007001200003